Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

IMPROVEMENTS OBSERVED IN KEY NON-INVASIVE MARKERS OF FIBROSIS ACROSS TREATMENT ARMS VERSUS PLACEBO, WITH CONTINUED REDUCTIONS FROM 24-WEEK TIMEPOINT

ALTIMMUNE ANNOUNCES THAT PEMVIDUTIDE ACHIEVED KEY MEASURES OF SUCCESS AT 48 WEEKS IN IMPACT PHASE 2B MASH TRIAL

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY OR ALT5) (NASDAQ: ALTS)(FRA: 5AR1), A FINTECH COMPANY OPERATING INSTITUTIONAL-GRADE GLOBAL PAYMENTS, TRADING, AND SETTLEMENT INFRASTRUCTURE, TODAY ISSUED THE FOLLOWING LETTER TO STOCKHOLDERS FROM CEO TONY ISAAC: DEAR FELLOW STOCKHOLDERS, AS I RETURN TO THE CEO ROLE AT ALT5, I AM FOCUSED ON IMMEDIATE EXECUTION AND TRANSPARENT COMMUNICATION TO UNLOCK THE SUBSTANTIAL VALUE EMBEDDED IN OUR BUSINESS. ALT5 HAS BUILT SOMETHING REMARKA.

ALT5 SIGMA CORPORATION ISSUES STOCKHOLDER LETTER FROM CEO TONY ISAAC

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY, OUR OR ALT5) (NASDAQ: ALTS) (FRA:5AR1), A FINTECH COMPANY WITH ESTABLISHED GLOBAL PAYMENTS, TRADING, AND SETTLEMENT INFRASTRUCTURE, TODAY RELEASED A STRATEGIC OVERVIEW ON THE USD1 STABLECOIN, ITS RELEVANCE TO ALT5'S CORE LONG-TERM PAYMENTS TECHNOLOGY PRODUCT, AND THE ANTICIPATED BENEFITS TO THE COMPANY'S $WLFI TREASURY STRATEGY. WHY USD1 MATTERS TO ALT5 ALT5 IS A LEADING HOLDER OF $WLFI, THE GOVERNANCE TOKEN OF THE WORLD LIB.

ALT5 SIGMA CORPORATION PROVIDES STRATEGIC OVERVIEW OF $WLFI TREASURY STRATEGY, USD1 STABLECOIN UTILITY AND ITS RELEVANCE TO THE COMPANY'S FUTURE PAYMENT INFRASTRUCTURE

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY OR ALT5) (NASDAQ: ALTS) (FRA:5AR1), A FINTECH COMPANY ADVANCING A STRATEGIC $WLFI DIGITAL ASSET TREASURY INITIATIVE, TODAY ISSUED A CORPORATE UPDATE. TONY ISSAC, PRESIDENT AND CEO OF ALT5 COMMENTED, ALT5'S FINTECH SUCCESS OVER THE PAST SEVERAL YEARS STEMS FROM OUR NIMBLE, STARTUP-DRIVEN APPROACH, ONE THAT ENABLED US TO ADAPT QUICKLY TO MARKET SHIFTS AND CAPITALIZE ON EMERGING OPPORTUNITIES. WE ARE FOCUSED ON RE-IGNITING THAT S.

ALT5 SIGMA CORPORATION PROVIDES CORPORATE UPDATE

LAS VEGAS--(BUSINESS WIRE)--ALT 5 SIGMA CORPORATION (THE COMPANY OR ALT5) (NASDAQ: ALTS)(FRA: 5AR1) TODAY ANNOUNCED THAT IT RECEIVED A NOTIFICATION LETTER (THE LETTER) FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) INDICATING THAT THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5250(C)(1) DUE TO ITS DELAY IN FILING ITS FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 27, 2025 (THE FORM 10-Q). ON NOVEMBER 12, 2025, THE COMPANY FILED A NOTIFICATION OF LATE FILING ON FORM 12B-25 WITH THE SE.

ALT5 SIGMA RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING LATE FILING OF FORM 10-Q

ALTIMMUNE ANNOUNCES CEO TRANSITION AND SUCCESSION PLAN UNDER WHICH JERRY DURSO WILL ASSUME THE ROLE OF PRESIDENT AND CHIEF EXECUTIVE OFFICER ON JANUARY 1.

ALTIMMUNE ANNOUNCES CEO TRANSITION AND SUCCESSION PLAN

GAITHERSBURG, MD., NOV. 26, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE. DETAILS ARE AS FOLLOWS:

ALTIMMUNE TO PARTICIPATE IN THE PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE

24-WEEK DATA DEMONSTRATED SIGNIFICANT MASH RESOLUTION AND WEIGHT LOSS, AND STRONG EVIDENCE OF ANTI-FIBROTIC ACTIVITY WITH A FAVORABLE TOLERABILITY PROFILE SIGNIFICANT IMPROVEMENTS OBSERVED IN SECONDARY ENDPOINTS, INCLUDING REDUCTIONS IN LIVER FAT, INFLAMMATION AND BIOMARKERS OF FIBROSIS GAITHERSBURG, MD., NOV. 11, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED PUBLICATION IN THE LANCET OF 24-WEEK EFFICACY AND SAFETY DATA FROM THE ONGOING IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN A PAPER TITLED SAFETY AND EFFICACY OF WEEKLY PEMVIDUTIDE VERSUS PLACEBO FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (IMPACT): 24-WEEK RESULTS FROM A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 2B STUDY.

ALTIMMUNE ANNOUNCES PUBLICATION OF IMPACT PHASE 2B TRIAL DATA IN THE LANCET AND CONCURRENT LATE-BREAKING ORAL PRESENTATION AT AASLD THE LIVER MEETING 2025

AI-BASED DIGITAL PATHOLOGY ANALYSIS PROVIDES HIGH-RESOLUTION QUANTIFICATION OF HEPATIC FIBROSIS AND OBJECTIVE MEASUREMENT OF FIBROSIS IMPROVEMENT

ALTIMMUNE PRESENTS AI-BASED ANALYSIS OF LIVER FIBROSIS REDUCTION FROM IMPACT PHASE 2B TRIAL OF PEMVIDUTIDE IN MASH IN LATE-BREAKING POSTER AT AASLD THE LIVER MEETING 2025

48-WEEK DATA FROM PHASE 2B IMPACT TRIAL OF PEMVIDUTIDE IN MASH EXPECTED BEFORE YEAR END END-OF-PHASE 2 MEETING WITH FDA FOR MASH PROGRAM SCHEDULED IN FOURTH QUARTER EXECUTIVE LEADERSHIP STRENGTHENED WITH APPOINTMENTS OF CHIEF MEDICAL OFFICER, CHIEF COMMERCIAL OFFICER, AND CHIEF LEGAL OFFICER CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $211 MILLION AS OF SEPTEMBER 30, 2025 WEBCAST TO BE HELD TODAY, NOVEMBER 6, 2025, AT 8:30 A.M. ET GAITHERSBURG, MD.

ALTIMMUNE ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

GAITHERSBURG, MD., NOV. 05, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE AND BE AVAILABLE FOR ONE-ON-ONE MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES: STIFEL 2025 HEALTHCARE CONFERENCE WEDNESDAY, NOVEMBER 12, 2025 FIRESIDE CHAT AT 10:00 A.M.

ALTIMMUNE TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

ENROLLMENT COMPLETED AHEAD OF SCHEDULE, UNDERSCORING STRONG INTEREST FROM PATIENT COMMUNITY IN A POTENTIAL NEW THERAPEUTIC OPTION ON TRACK TO COMPLETE THE 24-WEEK TREATMENT PERIOD AND ANNOUNCE TOPLINE RESULTS IN 2026 GAITHERSBURG, MD., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE COMPLETION OF PATIENT ENROLLMENT IN RECLAIM, A PHASE 2 CLINICAL TRIAL EVALUATING PEMVIDUTIDE IN ADULTS WITH ALCOHOL USE DISORDER (AUD).

ALTIMMUNE ANNOUNCES EARLY COMPLETION OF ENROLLMENT IN RECLAIM PHASE 2 TRIAL EVALUATING PEMVIDUTIDE IN ALCOHOL USE DISORDER

GAITHERSBURG, MD., OCT. 30, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT IT WILL REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 6, 2025.

Altimmune, Inc.

ALT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Altimmune, Inc.

ALT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ALT